Lovisa Afzelius
About Lovisa Afzelius
Founding CEO & Director of Elsa.science
Lovisa Afzelius is the Founding CEO and Director of Elsa.science, a digital health company specializing in the rheumatoid arthritis space. She co-founded the company with the aim of providing innovative digital solutions for managing rheumatoid arthritis. Her leadership has been pivotal in driving the company’s mission and strategic initiatives.
Academic Background in Computational Chemistry and Pharmacology
Lovisa Afzelius holds a Ph.D. in computational chemistry from Uppsala University and a Master of Science in integrative pharmacology from Gothenburg University. She further enhanced her academic credentials by completing an MBA from the MIT Sloan School of Management. Her strong educational foundation underpins her expertise in both the scientific and business aspects of her work.
Professional Experience at Pfizer
Lovisa Afzelius has a notable history with Pfizer, where she built and led the systems immunology function. Additionally, she served as the executive director of clinical programs, launching several Phase 2 studies across autoimmune indications. Her work at Pfizer underscored her capacity to manage complex clinical studies and contribute to the advancement of immunological research.
Previous Role as CEO of BioChromix Pharma
Before relocating to the United States in 2013, Lovisa Afzelius was the CEO of BioChromix Pharma. In this role, she was responsible for guiding the company through its strategic and operational initiatives, reflecting her strong leadership abilities within the pharmaceutical industry.
Board Membership and Industry Recognition
Lovisa Afzelius serves on the board of the Swedish New England Chamber of Commerce. Her industry recognition includes being named to the PharmaVoice 100 list of life science industry leaders in 2023 and being included in the top 100 'most influential persons under age 40 in Sweden' by Affärsvärlden. She also received the Rosenön Award for her outstanding thesis in pharmacodynamics/pharmacokinetics in Sweden, underscoring her contributions to the field.